Literature DB >> 27547014

Hepatitis C virus G1b infection decreases the number of small low-density lipoprotein particles.

Chika Kinoshita1, Tomohisa Nagano1, Nobuyoshi Seki1, Yoichi Tomita1, Tomonori Sugita1, Yuta Aida1, Munenori Itagaki1, Kenichi Satoh1, Satoshi Sutoh1, Hiroshi Abe1, Akihito Tsubota1, Yoshio Aizawa1.   

Abstract

AIM: To investigate how hepatitis C virus (HCV) G1b infection influences the particle number of lipoproteins.
METHODS: The numbers of lipoprotein particles in fasting sera from 173 Japanese subjects, 82 with active HCV G1b infection (active HCV group) and 91 with cleared HCV infection (SVR group), were examined. Serum lipoprotein was fractionated by high-performance liquid chromatography into twenty fractions. The cholesterol and triglyceride concentrations in each fraction were measured using LipoSEARCH. The number of lipoprotein particles in each fraction was calculated using a newly developed algorithm, and the relationship between chronic HCV G1b infection and the lipoprotein particle number was determined by multiple linear regression analysis.
RESULTS: The median number of low-density lipoprotein (LDL) particles was significantly lower in the active HCV group [1182 nmol/L, interquartile range (IQR): 444 nmol/L] than in the SVR group (1363 nmol/L, IQR: 472 nmol/L, P < 0.001), as was that of high-density lipoprotein (HDL) particles (14168 nmol/L vs 15054 nmol/L, IQR: 4114 nmol/L vs 3385 nmol/L, P = 0.042). The number of very low-density lipoprotein (VLDL) particles was similar between the two groups. Among the four LDL sub-fractions, the number of large LDL particles was similar between the two groups. However, the numbers of medium (median: 533.0 nmol/L, IQR: 214.7 nmol/L vs median: 633.5 nmol/L, IQR: 229.6 nmol/L, P < 0.001), small (median: 190.9 nmol/L, IQR: 152.4 nmol/L vs median: 263.2 nmol/L, IQR: 159.9 nmol/L; P < 0.001), and very small LDL particles (median: 103.5 nmol/L, IQR: 66.8 nmol/L vs median: 139.3 nmol/L, IQR: 67.3 nmol/L, P < 0.001) were significantly lower in the active HCV group than in the SVR group, respectively. Multiple linear regression analysis indicated an association between HCV G1b infection and the decreased numbers of medium, small, and very small LDL particles. However, active HCV infection did not affect the number of large LDL particles or any sub-fractions of VLDL and HDL particles.
CONCLUSION: HCV G1b infection decreases the numbers of medium, small, and very small LDL particles.

Entities:  

Keywords:  Cholesterol; Chronic hepatitis C; Lipoprotein particles; Low-density lipoproteins; Regression analysis; Triglycerides; Very low-density lipoproteins

Mesh:

Substances:

Year:  2016        PMID: 27547014      PMCID: PMC4970482          DOI: 10.3748/wjg.v22.i29.6716

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  62 in total

1.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

Authors:  M A Austin; M C King; K M Vranizan; R M Krauss
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

Review 2.  Metabolic origins and clinical significance of LDL heterogeneity.

Authors:  Kaspar K Berneis; Ronald M Krauss
Journal:  J Lipid Res       Date:  2002-09       Impact factor: 5.922

3.  Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices.

Authors:  Thomas G Cole; John H Contois; Gyorgy Csako; Joseph P McConnell; Alan T Remaley; Sridevi Devaraj; Daniel M Hoefner; Tonya Mallory; Amar A Sethi; G Russell Warnick
Journal:  Clin Chem       Date:  2013-02-05       Impact factor: 8.327

4.  Development and application of a multicompartmental model to study very low density lipoprotein subfraction metabolism.

Authors:  C J Packard; A Gaw; T Demant; J Shepherd
Journal:  J Lipid Res       Date:  1995-01       Impact factor: 5.922

5.  Apolipoprotein c1 association with hepatitis C virus.

Authors:  Jean-Christophe Meunier; Rodney S Russell; Ronald E Engle; Kristina N Faulk; Robert H Purcell; Suzanne U Emerson
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

Review 6.  Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs.

Authors:  G D Kolovou; K K Anagnostopoulou; P M Kostakou; D P Mikhailidis
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

7.  Low-density lipoprotein subclass patterns and risk of myocardial infarction.

Authors:  M A Austin; J L Breslow; C H Hennekens; J E Buring; W C Willett; R M Krauss
Journal:  JAMA       Date:  1988-10-07       Impact factor: 56.272

8.  Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study.

Authors:  Chia-Yen Dai; Wan-Long Chuang; Chi-Kung Ho; Ming-Yen Hsieh; Jee-Fu Huang; Li-Po Lee; Nai-Jen Hou; Zu-Yau Lin; Shinn-Cherng Chen; Ming-Yuh Hsieh; Liang-Yen Wang; Jun-Fa Tsai; Wen-Yu Chang; Ming-Lung Yu
Journal:  J Hepatol       Date:  2008-04-22       Impact factor: 25.083

9.  Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects.

Authors:  C J Packard; A Munro; A R Lorimer; A M Gotto; J Shepherd
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

10.  Association between hepatitis C virus core protein and carotid atherosclerosis.

Authors:  Yuko Ishizaka; Nobukazu Ishizaka; Eiko Takahashi; Tadao Unuma; Ei-ichi Tooda; Hideki Hashimoto; Ryozo Nagai; Minoru Yamakado
Journal:  Circ J       Date:  2003-01       Impact factor: 2.993

View more
  1 in total

1.  Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate.

Authors:  Shizuya Yamashita; Mitsuyo Okazaki; Takeshi Okada; Daisaku Masuda; Koutaro Yokote; Hidenori Arai; Eiichi Araki; Shun Ishibashi
Journal:  J Atheroscler Thromb       Date:  2021-02-02       Impact factor: 4.928

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.